IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.
2024年8月8日 - 9:00PM
via IBN – IBN, a multifaceted communications organization engaged
in connecting public companies to the investment community, is
pleased to announce the release of the latest episode of The
BioMedWire Podcast as part of its sustained effort to provide
specialized content distribution via widespread syndication
channels.
The BioMedWire Podcast features fast-paced interviews with
experts guiding the next wave of pharmaceutical and biotech
innovation. The latest episode features Rob Etherington, President
and CEO of Clene Inc. (NASDAQ: CLNN), a late clinical-stage
biopharmaceutical company focused on improving mitochondrial health
and protecting neuronal function to treat neurodegenerative
diseases.
To begin the interview, Etherington discussed Clene’s mission,
including its novel approach to the treatment of diseases such as
amyotrophic lateral sclerosis (ALS) and multiple sclerosis
(MS).
“Clene Inc. is focused entirely on improving mitochondrial
health and protecting neuron function. This is a very important
thing we can do to treat neurodegenerative diseases such as ALS, MS
and Parkinson's,” he said. “This is particularly topical today,
because the World Health Organization is predicting that
neurodegenerative diseases will become the second-most prevalent
cause of death within the next two decades. We're pioneering a very
unique approach: the use of an oral suspension that patients can
drink to treat the deficits that they might have if afflicted with
one of these devastating neurodegenerative diseases.”
“ALS is historically known as Lou Gehrig’s disease, famously
named after the baseball player who contracted it in the 1930s.
From there, it took 60 years for the first ALS drug to be approved
by the FDA. It was approved in 1995 and still remains today, nearly
three decades later, the standard of care. There's obviously a
tremendous need for new drugs in ALS. In the case of multiple
sclerosis, there are a lot of drugs that can treat MS, but they all
do effectively the same thing: they tamp down the body's immune
response, so the body stops attacking itself. What they don’t do is
improve function – the way patients move and walk and talk and
think cognitively with MS.”
“To put it simply, our brains are about 3-5% of our body weight
but consumes around 25% of our energy every day. Night and day, we
are powering our central nervous system to help us move and walk
and talk and eat and chew and breathe, but, in neurodegenerative
diseases, the neuron loses the ability to talk to the muscles and
enable us to do the things that we take for granted. What we're
doing is improving the vital dysfunction and the bioenergetic
metabolite that our neurons rely upon to continue this function.
Our drug enables the energetic capacity that those muscles require
to function and, in the case of ALS, enables the main systems,
primarily breathing, to be muscularly sustained so patients
potentially have increased rates of survival, as our data
suggests.”
Join IBN’s Carmel Fisher and Rob Etherington, President and CEO
of Clene Inc., to learn more about the company’s development
pipeline, including recent milestones from its VISIONARY-MS and
REPAIR-MS clinical programs.
To hear the episode and subscribe for future podcasts,
visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to
reinforce IBN’s commitment to the expansion of its robust network
of brands, client partners, followers, and the growing IBN Podcast
Series. For more than 18 years, IBN has leveraged this commitment
to provide unparalleled distribution and corporate messaging
solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline, visit: https://IBN.fm/TimeLine
About IBN
IBN consists of financial brands introduced to the investment
public over the course of 18+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1)
access to a network of wire solutions via InvestorWire to reach all
target markets, industries and demographics in the most effective
manner possible; (2) article and editorial syndication to 5,000+
news outlets; (3) Press Release Enhancement to ensure maximum
impact; (4) full-scale distribution to a growing social media
audience; (5) a full array of corporate communications solutions;
and (6) total news coverage solutions.
For more information, please visit
https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Clene (NASDAQ:CLNN)
過去 株価チャート
から 9 2024 まで 10 2024
Clene (NASDAQ:CLNN)
過去 株価チャート
から 10 2023 まで 10 2024